[1]
|
V. Toschi and F. Baudo, “Diagnosis, Laboratory Aspects and Management of Acquired Hemophilia A,” Internal and Emergency Medicine, Vol. 5, No. 4, 2010, pp. 325- 333. doi:10.1007/s11739-010-0380-y
|
[2]
|
A. Huth-Kühne, F. Baudo, P. Collins, J. Ingerslev, C. M. Kessler, H. Lévesque, M. Castellano, M. Shima M and J. St-Louis, “International Recommendations on the Diagnosis and Treatment of Patients with Acquired Hemophilia A,” Haematologica, Vol. 94, No. 4, 2009, pp. 566-575.
|
[3]
|
M. Franchini, D. Veneri, G. Lippi and R. Stenner, “The Efficacy of Rituximab in the Treatment of Inhibitor Associated Hemostatic Disorders,” Journal of Thrombosis and Haemostasis, Vol. 96, No. 2, 2006, pp. 119-125.
|
[4]
|
M. Franchini, G. Gandini, T. Di Paolantonio and G. Mariani, “Acquired Haemophilia A: A Concise Review,” American Journal of Hematology, Vol. 80, No. 1, 2005, pp. 55-63. doi:10.3324/haematol.2009.017749
|
[5]
|
M. Wermke, M. von Bonin, S. Gehrisch, G. Siegert, G. Ehninger and U. Platzbecker, “Successful Eradication of Acquired Factor-VIII-Inhibitor Using Single Low-Dose Rituximab,” Haematologica, Vol. 95, No. 3, 2010, pp. 521-522. doi:10.3324/haematol.2009.017749
|